What the FDA labels say about taking them together
Dihydroergotamine and nicotine
Dihydroergotamine's FDA label of March 6, 2025 names nicotine in its drug interactions section; the nicotine labels PlainMeds reads (2) do not name dihydroergotamine. The dihydroergotamine label: “DRUG INTERACTIONS Beta Blockers/Nicotine: May potentiate/provoke vasoconstriction Selective Serotonin Reuptake Inhibitors:”
Check it at the source: the dihydroergotamine FDA label on DailyMed (effective March 6, 2025, Oceanside Pharmaceuticals); the nicotine FDA label on DailyMed (effective July 25, 2024, Dr. Reddys Laboratories Inc.).
What does the dihydroergotamine label say about nicotine?
Dihydroergotamine label, drug interactionsNicotine Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.
Trudhesa label (Impel Pharmaceuticals LLC, September 3, 2026), drug interactionsDRUG INTERACTIONS Beta Blockers/Nicotine: May potentiate/provoke vasoconstriction ( 7.3 , 7.5 ) Selective Serotonin Reuptake Inhibitors:
Atzumi label (Satsuma Pharmaceuticals, Inc., June 22, 2026), drug interactionsDRUG INTERACTIONS Beta Blockers/Nicotine: May potentiate/provoke vasoconstriction.
Source: FDA drug label (Trudhesa, NDA213436), Impel Pharmaceuticals LLC, effective September 3, 2026 (SPL set b81397b0-910d-4eb4-8fee-a9a3c9d94d63), via openFDA
Source: FDA drug label (Atzumi, NDA217901), Satsuma Pharmaceuticals, Inc., effective June 22, 2026 (SPL set 0982a44a-dc0c-75c0-e063-6394a90a6d6c), via openFDA
Source: FDA drug label (Dihydroergotamine Mesylate), NDA020148 (Bausch), as published by Oceanside Pharmaceuticals, effective March 6, 2025 (SPL set 977de209-c53a-4cb4-9f3f-1e850600a9dc), via openFDA; the full label on DailyMed
What does the nicotine label say about dihydroergotamine?
Nicotine's label (effective July 25, 2024) and its 1 other brand-application label do not name dihydroergotamine in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Nicotine transdermal system), Dr. Reddys Laboratories Inc., effective July 25, 2024 (SPL set e2391b29-9bac-fc09-f2a5-a3370bc4e2c3), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dihydroergotamine | Nicotine | |
|---|---|---|
| Labeled for | Migraine | Quitting smoking |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $29.44 per mL 4 mg/mL nasal spray | $1.87 per patch 21 mg/24hr patch |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once